Reagan-Udall Foundation and Friends of Cancer Research form COVID-19 Evidence Accelerator focused on RWE

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Reagan-Udall Foundation for the FDA and Friends of Cancer Research, created the Evidence Accelerator, a public-private partnership combining the efforts of academic, government, and private sector organizations applying data analytics to accelerate the understanding of COVID-19.

Mobilizing major data organizations, government and academic researchers, and health systems, the Evidence Accelerator builds on the work of its partners to maximize the use of real-world data. Contributing researchers will engage in weekly meetings to present and critically discuss findings from different data sources. In addition, the Evidence Accelerator will facilitate parallel analyses of questions to identify patient characteristics, treatment patterns, and management strategies for COVID-19.

Table of Contents

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login